• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低巴氏指数评分是新诊断的多发性骨髓瘤患者的不良预后因素。

Low Barthel index score is a poor prognostic factor for newly diagnosed multiple myeloma patients.

作者信息

Geng Chuanying, Yang Guangzhong, Zhou Huixing, Wang Huijuan, Li Yanchen, Leng Yun, Zhang Zhiyao, Jian Yuan, Chen Wenming

机构信息

Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, China.

出版信息

Clin Exp Med. 2023 Oct;23(6):2593-2600. doi: 10.1007/s10238-023-01002-7. Epub 2023 Jan 26.

DOI:10.1007/s10238-023-01002-7
PMID:36703087
Abstract

The basic activities of daily life may affect the prognosis of multiple myeloma (MM) patients and the Barthel index (BI) is currently the most widely used tool to evaluate basic activities of daily life, but few studies have evaluated its prognostic value in MM. We retrospectively enrolled patients with newly diagnosed MM and analyzed the association between the BI and the survival of newly diagnosed MM patients. We totally analyzed 538 patients and found that median overall survival (OS) and progression-free survival (PFS) were significantly shorter in the low BI (≤ 85) group compared with the high BI (> 85) group. Univariate Cox proportional hazards regression analysis showed that the low BI was associated with shorter OS and PFS. It was also confirmed that the low BI was poor prognostic factor for OS and PFS in multivariable analyses. In the propensity score matching analysis, patients with low BI also had shorter OS and PFS. Our study suggested that the low BI was a poor prognostic factor for patients with newly diagnosed MM.

摘要

日常生活的基本活动可能会影响多发性骨髓瘤(MM)患者的预后,巴氏指数(BI)是目前评估日常生活基本活动最广泛使用的工具,但很少有研究评估其在MM中的预后价值。我们回顾性纳入新诊断的MM患者,并分析BI与新诊断MM患者生存之间的关联。我们共分析了538例患者,发现低BI(≤85)组的中位总生存期(OS)和无进展生存期(PFS)明显短于高BI(>85)组。单因素Cox比例风险回归分析显示,低BI与较短的OS和PFS相关。多变量分析也证实,低BI是OS和PFS的不良预后因素。在倾向评分匹配分析中,低BI患者的OS和PFS也较短。我们的研究表明,低BI是新诊断MM患者的不良预后因素。

相似文献

1
Low Barthel index score is a poor prognostic factor for newly diagnosed multiple myeloma patients.低巴氏指数评分是新诊断的多发性骨髓瘤患者的不良预后因素。
Clin Exp Med. 2023 Oct;23(6):2593-2600. doi: 10.1007/s10238-023-01002-7. Epub 2023 Jan 26.
2
Prognostic value of t(4;14) translocation in newly diagnosed multiple myeloma patients in novel agent era.新型药物时代新诊断多发性骨髓瘤患者中t(4;14)易位的预后价值
Hematology. 2023 Dec;28(1):2161222. doi: 10.1080/16078454.2022.2161222.
3
Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients.深度和部分免疫抑制是新诊断多发性骨髓瘤患者的预后不良因素。
Leuk Lymphoma. 2021 Apr;62(4):883-890. doi: 10.1080/10428194.2020.1855345. Epub 2020 Dec 4.
4
[Prognostic Value of CD56 Expression in Newly Diagnosed Multiple Myeloma Patients and Its Related Factors].[CD56表达在新诊断多发性骨髓瘤患者中的预后价值及其相关因素]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Jun;31(3):777-782. doi: 10.19746/j.cnki.issn.1009-2137.2023.03.023.
5
The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma.凝血酶原时间和活化部分凝血活酶时间在新诊断多发性骨髓瘤患者中的预后作用
Biomed Res Int. 2021 May 19;2021:6689457. doi: 10.1155/2021/6689457. eCollection 2021.
6
High Expression of Phosphorylated Extracellular Signal-Regulated Kinase (ERK1/2) is Associated with Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma.磷酸化细胞外信号调节激酶(ERK1/2)的高表达与新诊断的多发性骨髓瘤患者的不良预后相关。
Med Sci Monit. 2017 May 30;23:2636-2643. doi: 10.12659/msm.901850.
7
[The Prognostic Value of Del(1p32) in Patients with Newly Diagnosed Multiple Myeloma].[Del(1p32)在新诊断多发性骨髓瘤患者中的预后价值]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Jun;32(3):768-773. doi: 10.19746/j.cnki.issn.1009-2137.2024.03.017.
8
[The prognostic relationship between CD56 expression and newly diagnosed multiple myeloma].[CD56表达与新诊断多发性骨髓瘤的预后关系]
Zhonghua Nei Ke Za Zhi. 2022 Feb 1;61(2):164-171. doi: 10.3760/cma.j.cn112138-20210420-00296.
9
[A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].[一项关于自体造血干细胞移植与新药化疗治疗新诊断多发性骨髓瘤的倾向评分匹配研究]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Feb;30(1):158-165. doi: 10.19746/j.cnki.issn.1009-2137.2022.01.026.
10
Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation.新诊断的多发性骨髓瘤患者伴有 CD56 表达,从自体干细胞移植中获益更多。
BMC Cancer. 2022 Dec 23;22(1):1349. doi: 10.1186/s12885-022-10382-0.

引用本文的文献

1
Soft Tissue Sarcoma with Lower Limb Impairment: Development of a Specific Rehabilitation Protocol Based on Demolitive and Reconstructive Surgery Types.伴有下肢功能障碍的软组织肉瘤:基于破坏性和重建性手术类型制定特定康复方案
J Clin Med. 2024 Nov 21;13(23):7023. doi: 10.3390/jcm13237023.

本文引用的文献

1
Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results.来那度胺联合环磷酰胺和地塞米松治疗复发或难治性多发性骨髓瘤:MUKeight 期随机对照试验结果。
Blood Cancer J. 2022 Apr 1;12(4):52. doi: 10.1038/s41408-022-00626-4.
2
Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting.新诊断多发性骨髓瘤治疗前及治疗期间的风险分层:从临床试验到真实世界环境
Front Oncol. 2022 Mar 9;12:830922. doi: 10.3389/fonc.2022.830922. eCollection 2022.
3
Promising therapeutic approaches for relapsed/refractory multiple myeloma.
复发/难治性多发性骨髓瘤的有前途的治疗方法。
Hematology. 2022 Dec;27(1):343-352. doi: 10.1080/16078454.2022.2045724.
4
Current approaches to management of newly diagnosed multiple myeloma.初诊多发性骨髓瘤的治疗方法。
Am J Hematol. 2022 May;97 Suppl 1:S3-S25. doi: 10.1002/ajh.26512. Epub 2022 Mar 10.
5
Diagnosis and Management of Multiple Myeloma: A Review.多发性骨髓瘤的诊断与治疗:综述
JAMA. 2022 Feb 1;327(5):464-477. doi: 10.1001/jama.2022.0003.
6
Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study.在含卡非佐米方案治疗复发/难治性多发性骨髓瘤中,衰弱、较差的体能状态和高龄对临床的影响:KOTOSG 多中心前瞻性观察研究的事后调查。
Int J Hematol. 2022 Mar;115(3):350-362. doi: 10.1007/s12185-021-03262-z. Epub 2022 Jan 24.
7
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.达雷妥尤单抗联合来那度胺和地塞米松治疗不适合移植的新诊断多发性骨髓瘤:MAIA 研究脆弱亚组分析。
Leukemia. 2022 Apr;36(4):1066-1077. doi: 10.1038/s41375-021-01488-8. Epub 2022 Jan 2.
8
Research progress on treatment of extramedullary multiple myeloma.髓外多发性骨髓瘤的治疗研究进展。
Hematology. 2021 Dec;26(1):985-994. doi: 10.1080/16078454.2021.2005310.
9
Development of a new clinical index to easily assess frailty of elderly patients with multiple myeloma in Asian population.开发一种新的临床指标,以便在亚洲人群中轻松评估多发性骨髓瘤老年患者的虚弱程度。
Sci Rep. 2021 Nov 25;11(1):22907. doi: 10.1038/s41598-021-02433-6.
10
Daratumumab for the treatment of multiple myeloma.达雷妥尤单抗用于治疗多发性骨髓瘤。
Drugs Today (Barc). 2021 Oct;57(10):591-605. doi: 10.1358/dot.2021.57.10.3313853.